20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Avadel Pharmaceuticals plc's (NASDAQ:AVDL) shares are up Monday after the FDA granted final approval to Lumryz, an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.
- Narcolepsy is a chronic neurological disorder that affects the brain's ability to control the sleep-wake cycle.
- With final approval, Lumryz becomes the first and only FDA-approved once-at-bedtime oxybate for narcolepsy.
- The FDA additionally granted Lumryz Orphan Drug Exclusivity.
- The seven-year market exclusivity for Lumryz began on the date of FDA approval, May 1, 2023.
- In July 2022, the FDA tentatively approved Lumryz for cataplexy or EDS in adults with narcolepsy.
- Avadel submitted a minor amendment to the FDA on March 1, 2023, requesting the final approval of Lumryz.
- This minor amendment submission occurred shortly after delisting the REMS Patent from FDA's Orange Book by Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) in response to the unanimous 3-0 panel decision by the United States Court of Appeals for the Federal Circuit.
- Lumryz has a boxed warning as a central nervous system depressant and for its potential for abuse and misuse.
- Price Action: AVDL shares are up 11.35% at $11.67 on the last check Monday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!